Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2026-A00299-42 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Novo Nordisk A/S | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SEMAFOLLOW study population | Patient agreeing to participate in the SEMAFOLLOW study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SEMAFOLLOW questionnaire | Other | If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Describe weight changes during the follow-up period according to patient characteristics. | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors. | Baseline | |
| Compare the profiles of responders and non-responders | Baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
• Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection
Not provided
Not provided
Not provided
Patients treated with WEGOVY® (semaglutide 2.4 mg) under temporary authorization for use (ATU) and the early access program in France.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| David JACOBI | Contact | +332 53 48 28 35 | David.Jacobi@univ-nantes.fr |
| Name | Affiliation | Role |
|---|---|---|
| David JACOBI | Nantes University Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nantes university hospital | Nantes | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D050177 | Overweight |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
Not provided
Not provided
Not provided
| Describe weight change according to different subpopulations. | Baseline |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |